Kai Larson currently serves as  Vice President of Business Development and General Counsel for Signpath Pharma, a company which is developing drugs for the treatment of cancer and drug-induced cardiac arrhythmias.   He is a graduate of Brigham Young University and Columbia University School of Law, and began his career in the intellectual property department at the law firm of Kirkland & Ellis.  He has been involved in the pharmaceutical industry for more than twenty years, including serving as General Counsel for NaPro BioTherapeutics and Tapestry Pharmaceuticals.